Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2002

View Archived Issues

Novel dual mechanism of action reported for CP-248

K(ATP) channel opener KCO-912 effective against allergen-induced airways hyperresponsiveness

Medarex acquires anticancer and immunotherapeutic programs from Corixa

AUA presentations discuss use of tamsulosin for BPH

Monoamine reuptake inhibitors claimed by Lilly

Welfide describes novel C5a antagonists

Tachykinin antagonists and their use described by Takeda

Novel antiarrhythmic agent claimed by AstraZeneca

G-CSF-like compounds in the SSP pipeline

Inhibitors of 5alpha-reductase highlighted at the AUA meeting

New approaches to bladder cancer management discussed in Orlando this week

Antitumor effects of COX and 5-LO inhibitors under evaluation by several research groups

Data from basic and clinical studies on prostate cancer reported at AUA

Lovastatin may be useful in airways disorders

New data on PPARgamma ligands presented at the ATS conference

Clinical efficacy of oral pirfenidone as a treatment for pulmonary fibrosis

Inhibitors of phosphate transport and their use in renal failure, etc.

Sankyo patents triglyceride-lowering agents

Antiasthmatic NK2 antagonists in early development at Nippon Kayaku

Eligard 7.5 mg launched for advanced prostate cancer

Ethypharm licenses U.S. rights to twice-daily morphine sulfate to aaiPharma

MRA completes phase II trial in rheumatoid arthritis

Ethypharm and Aventis collaborate to create Flash version of Allegra

ATS presentations describe efficacy of statin in pulmonary hypertension

Synagis approved in Canada for RSV-induced lower respiratory tract disease

Merck & Co. to develop Taisho's mGluR agonists for CNS disorders

Ebixa approved in E.U. for Alzheimer's disease